Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Joan A. Keiser"'
Autor:
Winter Steven Mark, Joan A. Keiser, David Austen Perry, Eileen R. Blasi, Michael J. DePasquale, William T. Loging, Delvin R. Knight, Gregory W Cadelina
Publikováno v:
Drug Development Research. 70:35-48
ILLUMINATE, the Phase 3 clinical trial of morbidity and mortality (MM PF-868,348 is weakly potent and CP-746,281 and CE-308,958 are CETP-inactive. Changes in blood pressure were determined in conscious animals in conjunction with pharmacologic blocka
Publikováno v:
Pharmacology and Toxicology. 95:76-80
CI-1023 (AdGVVEGF121.10) is a replication-deficient adenovirus vector (complete E1a-, partial E1b-, partial E3-) delivering human vascular endothelial growth factor-121 gene. Previous studies from this group have established that CI-1023 can successf
Publikováno v:
Biochemical and Biophysical Research Communications. 315:363-368
This study examined whether retarded angiogenesis in a hypertension animal model was associated with impaired VEGF signaling. Furthermore, we sought to determine whether this impairment could be overcome by VEGF addition. Using a rat sponge implantat
Autor:
JE June, Paul D. Kessler, J T Bruder, Wendy Rosebury, Imre Kovesdi, LA Perrin, D Gordon, Andrew Robertson, Joan A. Keiser
Publikováno v:
Gene Therapy. 11:512-521
Adenovirus-mediated VEGF gene delivery is being evaluated in clinical trials as a treatment for patients with vascular diseases that stem from ischemia, such as diffuse coronary artery disease and peripheral vascular disease. Although adenoviral vect
Autor:
Martin B. Leon, Anthony Pierre, Joan A. Keiser, M. A. Flynn, Stephen E. Epstein, David A Gordon, Shmuel Fuchs, Yoram Vodovotz, Ran Kornowski, Imre Kovesdi
Publikováno v:
Journal of the American College of Cardiology. 35(4):1031-1039
OBJECTIVES To test the feasibility of myocardial angiogenic gene expression using a novel catheter-based transendocardial injection system. BACKGROUND Angiogenesis has been induced by direct injection of growth factors into ischemic myocardium during
Publikováno v:
Journal of Cardiovascular Pharmacology. 32:935-943
The purpose of this study was to determine whether vascular endothelial and vascular smooth-muscle endothelin ET B receptors could be quantitatively differentiated by PD 142893 (PD), SB 209670 (SB), and BQ 788 (BQ) in the same species by using closel
Autor:
Joan A. Keiser, He Wang
Publikováno v:
Circulation Research. 83:832-840
Abstract —Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis that stimulates proliferation, migration, and proteolytic activity of endothelial cells. Although the mitogenic activity of VEGF is endothelial cell specifi
Autor:
Brian G. Hartl, Randy Steinkampf, T C Major, Joan A. Keiser, Tawny K. Dahring, H. D. Hollis Showalter, Gina H. Lu, Alan J. Kraker, Robert L. Panek, Hussein Hallak, Brian L. Batley, Zhipei Wu, Bill J. Roberts, Sylvester Klutchko, Sandra J. Patmore, William L. Elliott, Laura A. Bradford, Wayne D. Klohs, Annette Marian Doherty, James Marino Hamby, Diane H. Boschelli
Publikováno v:
Journal of Medicinal Chemistry. 41:4365-4377
Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (1) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src
Molecular characterization of rabbit CPP32 and its function in vascular smooth muscle cell apoptosis
Autor:
Joan A. Keiser, He Wang
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 274:H1132-H1140
Vascular remodeling in atherogenesis is marked not only by cellular proliferation and migration but is also impacted by apoptotic cell death. Extensive studies have focused on the signal transduction events leading to apoptosis. CPP32, a member of th
Autor:
Richard L Schroeder, S. J. Haleen, Joan A. Keiser, Hussein Hallak, Edie Quenby-Brown, Donnelle M. Walker, Andrew C.G. Uprichard, Kathleen M. Welch
Publikováno v:
Journal of Cardiovascular Pharmacology. 31:S331-S335
We previously showed that CI-1020, an endothelin (ET)-A-selective receptor antagonist, dose-dependently blocked acute hypoxic pulmonary hypertension (PH) in rats. In this study we show that CI-1020 can reverse existing PH and prevent progression of r